Allarity Therapeutics Expanded In-House Lab Capabilities
The firm added proteomics research to its diagnostic operations to deepen analysis of its stenoparib drug candidate.
Updated on Sept. 28, 2026 in Biotech
Live Poll
Do you believe internal laboratory expansion by pharmaceutical companies benefits patients in the long term?
Allarity Therapeutics has expanded its in-house laboratory to include proteomics and cell line research alongside its existing transcriptomics services. This development is operational as of September 28, 2026.
Why it matters
These expanded capabilities are designed to provide more granular molecular insights into the mechanism of action for stenoparib. By integrating these services, the firm aims to support both internal research and potential external partnerships.
The laboratory now incorporates an nCounter Pro instrument capable of measuring approximately 300 protein targets. This setup complements the facility's existing transcriptomics and CLIA-certified testing workflows.
The players
Allarity Therapeutics
A clinical-stage biotechnology firm focused on oncology, specializing in companion diagnostics and the development of stenoparib.
The details
The laboratory uses transcriptomic data—the study of RNA molecules to determine gene expression—combined with cell line research to profile signaling pathways. The new workflow centers on the nCounter Human Tumor Signaling Protein Panel, which allows for quantitative analysis of protein expression in tumor samples. These data support the development of stenoparib, a dual PARP and WNT pathway inhibitor; PARP inhibitors interfere with enzymes that repair damaged DNA, while WNT pathway inhibitors target cell signaling systems involved in cancer growth.
Timeline
September 28, 2026: Allarity Therapeutics announced the expansion of its laboratory capabilities.
The Tech Race
This move represents an attempt to integrate high-throughput proteomics into a diagnostic-led drug development pipeline. The company is positioning these capabilities to better characterize the activity of stenoparib against current industry standards for dual-pathway inhibitors.
The changes primarily affect the company's internal research workflows and its capacity to provide analytical services to outside partners. There is no anticipated change to the current corporate cash runway as a result of this infrastructure investment.
The takeaway
The expansion signals a shift toward vertical integration of diagnostic data in early-stage drug development. Future updates from the company will clarify how this expanded dataset informs the clinical trial trajectory for stenoparib.
Further reading
For broader context on current diagnostic integration in drug research, visit Biotech.
Live Poll
Do you believe internal laboratory expansion by pharmaceutical companies benefits patients in the long term?
